Nathan Buchbinder, Proscia’s Chief Strategy Officer, spoke to The Pathologist to unpack the findings of the “2023 Life Sciences Digital Pathology Adoption Survey.” This research that we commissioned asked 40 senior executives from major pharmaceutical companies and contract research organizations (CROs) about the extent to which they have implemented digital pathology and the benefits it is delivering.
Featured Story:
Latest Articles
October 1, 2024